Park Ha Biological Technology Co., Ltd. Announces Closing of a US$2.45 Million Public Offering

Rhea-AI Summary

Park Ha Biological Technology (NASDAQ: BYAH) closed a best-efforts follow-on offering of 21,875,000 units at US$0.112 per unit on January 28, 2026, generating approximately US$2.45 million in gross proceeds.

Each unit includes one Class A ordinary share and one warrant exercisable at US$0.112 through the one-year anniversary, with an alternative cashless exercise allowing up to nine shares. Net proceeds are intended to fund expansion of directly operated stores in China.

Positive

• Gross proceeds of approximately US$2.45 million
• Proceeds earmarked for expansion of directly operated stores in China

Negative

• 21,875,000 units issued, creating immediate share and warrant dilution
• Each warrant exercisable at US$0.112 for one share or cashless up to nine shares within one year

Key Figures

Units offered: 21,875,000 units Offering price: US$0.112 per Unit Gross proceeds: US$2.45 million +5 more

8 metrics

Units offered 21,875,000 units Best-efforts follow-on public offering

Offering price US$0.112 per Unit Follow-on public offering

Gross proceeds US$2.45 million Before placement commissions and expenses

Warrant exercise price US$0.112 per share Warrants in each Unit, exercisable for one year

Par value US$0.00002 per share Class A ordinary shares

Alternative cashless exercise cap Up to nine Class A shares Maximum per Warrant via alternative cashless exercise

Form F-1 file number 333-290410 Registration statement for the offering

F-1 effectiveness date January 26, 2026 SEC declared registration statement effective

Market Reality Check

Price: $0.3850 Vol: Volume 428,938 is 1.19x i...

normal vol

$0.3850 Last Close

Volume Volume 428,938 is 1.19x its 20-day average of 361,616. normal

Technical Shares at 0.385, trading well below the 200-day MA of 8.17 and near the 52-week low of 0.3573.

Peers on Argus

Only one peer, TANH, appeared in the momentum scanner, moving up 6.2799997627735...

1 Up

Only one peer, TANH, appeared in the momentum scanner, moving up 6.279999762773514% without related news. Other listed peers show mixed single-day moves, suggesting today’s offering is primarily stock-specific rather than sector-driven.

Historical Context

1 past event · Latest: Oct 24 (Neutral)

Pattern 1 events

Date	Event	Sentiment	Move	Catalyst
Oct 24	Ticker change	Neutral	+5.4%	Announced change of Nasdaq ticker symbol from PHH to BYAH.

Pattern Detected

Limited recent news history; the last disclosed event (ticker change) saw a positive price reaction aligned with neutral news.

Recent Company History

Over the past six months, disclosed news for Park Ha Biological Technology has been limited. On Oct 24, 2025, the company announced a Nasdaq ticker change from PHH to BYAH, aimed at clarifying branding without altering listing status or CUSIP. Shares reacted positively by 5.39% within 24 hours. Compared with that administrative update, today’s follow-on public offering represents a more material capital-raising step that can directly affect share count and near-term trading dynamics.

Market Pulse Summary

This announcement details a best-efforts follow-on public offering of 21,875,000 units at US$0.112, ...

Analysis

This announcement details a best-efforts follow-on public offering of 21,875,000 units at US$0.112, each with a share and a one-year warrant, raising gross proceeds of US$2.45 million. The capital is earmarked for expanding directly operated stores in China. Historically, the company has had sparse but impactful news, such as the Oct 24, 2025 ticker change. Investors may watch how warrant exercises at US$0.112 and use of proceeds influence liquidity, compliance milestones, and future corporate actions.

Key Terms

follow-on public offering, warrant, cashless exercise, exercise price, +3 more

7 terms

follow-on public offering financial

"announced the closing of a best-efforts follow-on public offering of 21,875,000 units"

An offering of new shares by a company that has already gone public, sold to investors to raise additional cash. Like a bakery cutting a larger cake to serve more customers, it increases the number of shares available which can lower each existing share’s claim on profits and ownership; investors watch these offerings because they can dilute current holdings, signal fundraising needs or growth plans, and often affect the stock price in the short term.

warrant financial

"and one warrant to purchase one Class A Ordinary Share, or up to nine Class A Ordinary Shares"

A warrant is a time-limited financial contract that gives its holder the right to buy a company's shares at a set price before a specified date, like a coupon that lets you purchase stock at a fixed discount for a limited time. It matters to investors because warrants offer leveraged exposure to a stock’s upside and can dilute existing shareholders if exercised, so they affect potential gains and the company’s outstanding share count.

cashless exercise financial

"or up to nine Class A Ordinary Shares pursuant to the alternative cashless exercise mechanism"

A cashless exercise is a way for an option holder to convert stock options into actual shares without paying the purchase price in cash; instead they immediately give up a portion of the newly issued shares to cover the cost and any withholding taxes. Investors care because this process increases the number of shares available and can slightly dilute existing holdings, while also signaling how insiders or employees are realizing compensation without needing cash — similar to paying for a purchase by handing over part of what you just bought.

exercise price financial

"Each Warrant has an exercise price of US$0.112 per Class A Ordinary Share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

registration statement on Form F-1 regulatory

"A registration statement on Form F-1, as amended (File No. 333- 290410), relating to the Offering"

A registration statement on Form F-1 is a legal document companies file with regulators to offer their shares to investors in a foreign country or market. It provides essential information about the company's business, finances, and risks, helping investors make informed decisions about whether to buy its stock. This process ensures transparency and protects investors by making company details publicly available before trading begins.

prospectus regulatory

"The Offering was made only by means of a prospectus, forming part of the effective registration statement."

A prospectus is a detailed document that explains a company's plans for offering new shares or investments to the public. It’s important because it provides potential investors with key information about the company’s business, risks, and how they might make money, helping them decide whether to invest. Think of it as a guidebook for understanding what you're buying into.

placement agent financial

"D. Boral Capital LLC acted as the Sole Placement Agent for the Offering."

A placement agent is a professional or firm that helps organizations raise money from investors, such as individuals, institutions, or funds. They act like matchmakers, connecting those seeking investments with the right investors and guiding the process to ensure successful funding. For investors, they can provide access to exclusive opportunities and help navigate complex fundraising efforts.

AI-generated analysis. Not financial advice.

Wuxi, China, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Park Ha Biological Technology Co., Ltd. (NASDAQ: BYAH) (the “Company”) today announced the closing of a best-efforts follow-on public offering of 21,875,000 units (each a “Unit”) at an offering price of US$0.112 per Unit.

Each Unit consists of one Class A ordinary share of the Company, par value US$0.00002 per share (each, a “Class A Ordinary Share”) and one warrant to purchase one Class A Ordinary Share, or up to nine Class A Ordinary Shares pursuant to the alternative cashless exercise mechanism described therein (each, a “Warrant”). Each Warrant has an exercise price of US$0.112 per Class A Ordinary Share and is exercisable beginning on the issuance date and ending on the one-year anniversary of the issuance date.

Gross proceeds to the Company, before deducting placement agent’s commissions and other offering expenses, were approximately US$2.45 million. The Company intends to use the net proceeds of the Offering for the expansion of directly operated stores in China, and the specific allocation of net proceeds to each market will be based on market conditions.

D. Boral Capital LLC acted as the Sole Placement Agent for the Offering.

A registration statement on Form F-1, as amended (File No. 333- 290410), relating to the Offering was filed with the U.S. Securities and Exchange Commission (the “SEC”) and was declared effective by the SEC on January 26, 2026. The Offering was made only by means of a prospectus, forming part of the effective registration statement. A copy of the final prospectus relating to the Offering has been filed with the SEC and is available on the SEC’s website at www.sec.gov. Copies of the prospectus may be obtained from D. Boral Capital LLC at info@dboralcapital.com, or by calling +1 (212) 970-5150.

About Park Ha Biological Technology Co., Ltd.

Established in 2016, Park Ha Biological Technology Co., Ltd. is primarily engaged in developing its private skincare label, direct skincare products sales and franchise alliances promotions under the proprietary brand “Park Ha”, with a commitment to providing cost-effective solutions to skin problems and improving the confidence of women in need of skin treatment. As of April 30, 2025, the Company has three directly operated stores and 39 franchisees, of which 38 and one operate under the store name “Park Ha” and “Geni” respectively, in China. As part of its value-added service for the products, the Company offers “light beauty experience”, a quick complimentary after-sales beauty service performed in the directly-operated stores and franchise stores. For more information, please visit the Company’s website: http://ir.parkha.cn/.

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can find many (but not all) of these statements by the use of words such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions in this announcement. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and other filings with the SEC.

For more information, please contact:

D. Boral Capital LLC
590 Madison Avenue, 39th Floor
New York, NY 10022
Main Phone: +1 (212) 970-5150
www.dboralcapital.com
info@dboralcapital.com

Park Ha Biological Technology Co., Ltd.
901, Building C
Phase 2, Wuxi International Life Science Innovation Campus
196 Jinghui East Road
Xinwu District, Wuxi, Jiangsu Province
People’s Republic of China 214000
http://ir.parkha.cn/
ir_parkha@163.com

FAQ

How many units did Park Ha Biological (BYAH) sell in the January 28, 2026 offering?

Park Ha sold 21,875,000 units in the offering. According to the company, each unit included one Class A ordinary share and one warrant exercisable for a share or cashless up to nine shares.

What price per unit and total gross proceeds did BYAH raise in the offering?

The offering price was US$0.112 per unit, raising about US$2.45 million gross. According to the company, this is before placement agent commissions and offering expenses.

What are the warrant terms in Park Ha Biological's (BYAH) follow-on offering?

Each warrant has an exercise price of US$0.112 and is exercisable immediately until the one-year anniversary. According to the company, warrants include an alternative cashless exercise enabling up to nine shares.

How does BYAH plan to use the net proceeds from the January 2026 offering?

Net proceeds will fund the expansion of directly operated stores in China. According to the company, allocation to each market will be based on prevailing market conditions.

Who acted as placement agent and was the offering registered with the SEC for BYAH?

D. Boral Capital LLC acted as the sole placement agent. According to the company, the Form F-1 registration (File No. 333-290410) was declared effective by the SEC on January 26, 2026.

When do the BYAH warrants expire and can they be exercised cashlessly?

Warrants expire one year after issuance and are exercisable from issuance date. According to the company, warrants permit an alternative cashless exercise mechanism converting to up to nine Class A shares.